HER2/neu Status on Pre and Post Neoadjuvant Chemotherapy

被引：0
|
作者：
Nofech-Mozes, S. [1 ]
Hanna, W. [1 ]
机构：
[1] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
来源：
MODERN PATHOLOGY | 2009年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
262
引用
收藏
页码：60A / 61A
页数：2
相关论文
共 50 条
  • [21] Evaluation of changes in the HR status and Her2 expression following neoadjuvant chemotherapy
    Ponce, C. R.
    Colo, F. A.
    Maino, M.
    Fabiano, V. Y.
    Loza, C. M.
    Amat, M.
    Nervo, A.
    Costanzo, V.
    Loza, J. B.
    Chacon, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Methodology Used to Determine HER2 Status Correlates with Response to Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer
    Cheng, Esther
    McIntire, Patrick
    D'Alfonso, Timothy
    Ginter, Paula
    LABORATORY INVESTIGATION, 2018, 98 : 54 - 54
  • [23] Response to a preventive HER2/neu peptide (E75) vaccine based on HER2/neu status
    Benavides, Linda C.
    Gates, Jeremy D.
    Carmichael, Mark G.
    Holmes, Jarrod P.
    Hueman, Matthew T.
    Mittendorf, Elizabeth A.
    Patil, Ritesh
    Stojadinovic, Alexander
    Craig, Dianna
    Ponniah, Sathibalan
    Peoples, George E.
    CANCER RESEARCH, 2008, 68 (09)
  • [24] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    Luciana de Moura Leite
    Marcelle Goldner Cesca
    Monique Celeste Tavares
    Debora Maciel Santana
    Erick Figueiredo Saldanha
    Paula Tavares Guimarães
    Daniella Dias Silva Sá
    Maria Fernanda Evangelista Simões
    Rafael Lima Viana
    Francisca Giselle Rocha
    Simone Klog Loose
    Sinara Figueiredo Silva
    Rafaela Pirolli
    Camilla Albina Zanco Fogassa
    Bruna Raphaeli Silva Mattos
    Fernando Augusto Batista Campos
    Solange Moraes Sanches
    Vladmir Cláudio Cordeiro de Lima
    Noam Falbel Pondé
    Breast Cancer Research and Treatment, 2021, 190 : 155 - 163
  • [25] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    de Moura Leite, Luciana
    Cesca, Marcelle Goldner
    Tavares, Monique Celeste
    Santana, Debora Maciel
    Saldanha, Erick Figueiredo
    Guimaraes, Paula Tavares
    Sa, Daniella Dias Silva
    Simoes, Maria Fernanda Evangelista
    Viana, Rafael Lima
    Rocha, Francisca Giselle
    Loose, Simone Klog
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla Albina Zanco
    Mattos, Bruna Raphaeli Silva
    Campos, Fernando Augusto Batista
    Sanches, Solange Moraes
    de Lima, Vladmir Claudio Cordeiro
    Ponde, Noam Falbel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 155 - 163
  • [26] Does Her2/neu status affect adjuvant chemotherapy utilization? A population based analysis
    Snow, S.
    Rayson, D.
    Barnes, P. J.
    Sellon, M.
    Thompson, K.
    Younis, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] HER2 and estrogen receptor status drive decisions regarding the use of neoadjuvant chemotherapy
    Love, N.
    Blackwell, K. L.
    Mamounas, E. P.
    Moss, J.
    Ziel, K.
    CANCER RESEARCH, 2016, 76
  • [28] Discordance in hormone receptor and HER2 status in breast cancer during neoadjuvant chemotherapy
    Maeda, S.
    Tohyama, H.
    Tokai, H.
    Kamohara, Y.
    Nagata, Y.
    Fujioka, H.
    Itoh, M.
    BREAST, 2011, 20 : S73 - S73
  • [29] Changes in Hormone Receptor and Her2 Status After Neoadjuvant Chemotherapy in Breast Cancer
    Kaya, Ali Osman
    Buyukberber, Suleyman
    Yamac, Deniz
    Coskun, Ugur
    Yildiz, Ramazan
    Yaman, Emel
    Ozturk, Banu
    Benekli, Mustafa
    TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2010, 30 (02): : 469 - 473
  • [30] Predictive Markers (ER, PR, HER2, HER2FISH) Pre- and Post-Neoadjuvant Chemotherapy in Primary Breast Carcinoma
    Darrow, M. D.
    Cohen, C.
    Nassar, A.
    MODERN PATHOLOGY, 2009, 22 : 36A - 36A
12345